Experimental Antibody Atezolizumab in cancer: Alveolar Soft Part Sarcoma

Enter your info and the study team will contact you soon!
Your data is securely stored and only shared with the research team
Data is not saved in preview.
"Study of experimental medicine for non-treatable alveolar soft part cancer"
6 to 120 years old
Healthy Volunteers:
alveolar soft part sarcoma, cancer, children, surgery, Immunotherapy
Drug study, Phase 2
Sometimes the advanced alveolar soft part sarcoma (ASPS) cancer cannot be helped with surgery or other treatment. The experimental drug atezolizumab unblocks the immune system. This allows immune cells to recognize and attack tumor cells. The drug could shrink cancer but could also have side effects. Researchers want to study if the drug will shrink a tumor in people with advanced ASPS. People at least 6 years old with ASPS that cannot be cured with surgery can participate in the study.
This study requires

Participants will be screened with heart and pregnancy tests. Some may have scans or other tests. The study may have multiple cycles. Each study cycle is 21 days. During the cycles participants may receive study drug through a vein, and blood draw tests, Some participants will have a tumor sample taken. Participants will have periodic tumor scans Participants can stay in the study as long as their cancer does not get worse. Participants will be observed for 30 days after stopping the study drug.

Who can participate

Inclusion criteria:

  • Patients must have histologically or cytologically confirmed Alveolar Soft Part Sarcoma that is not curable by surgery. Diagnosis of malignancy must be confirmed by the department of pathology at the institution where the patient is enrolled prior to patient enrollment.

  • Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for nonnodal lesions and short axis for nodal lesions) as greater than or equal to 20 mm (greater than or equal to 2 cm) by chest x-ray or as greater than or equal to 10 mm (greater than or equal to 1 cm) with CT scan, MRI, or calipers by clinical exam.

  • Patients with newly diagnosed, unresectable, metastatic and measureable ASPS who show clinical evidence of disease progression (including history and increasing physical symptoms) will also be eligible. On-study documentation will include a physician s rationale that supports evidence of clinical disease progression (i.e., increasing tumor pain).

  • Age greater than or equal to 6 years at the NCI clinical center (greater than or equal to 18 years at other participating sites)

  • ECOG performance status less than or equal to 2 (Karnofsky or Lansky greater than or equal to 70%,).

  • Life expectancy of greater than 3 months.

  • Patients must have normal organ and marrow function as defined below:

  • leukocytes: greater than or equal to 2,500/mcL

  • absolute neutrophil count: greater than or equal to 1,500/mcL

  • platelets: greater than or equal to 100,000/mcL

  • hemoglobin: greater than or equal to 8 g/dL

  • total bilirubin: less than or equal to 1.5 times institutional upper limit of normal (ULN) (however, patients with known Gilbert disease who have serum bilirubin level greater than or equal to 3 times ULN may be enrolled)

  • AST(SGOT)/ALT(SGPT) less than or equal to 3 times ULN (AST and/or ALT less than or equal to 5 times ULN for patients with liver involvement)

  • alkaline phosphatase less than or equal to 2.5 times ULN (less than or equal to 5 times ULN for patients with documented liver involvement or bone metastases)

  • creatinine clearance greater than or equal to 30 mL/min/1.73 m(2) by Cockcroft-Gault: (140 - age) times (weight in kg) times (0.85 if female)/72 times (serum creatinine in mg/dL)

  • Administration of atezolizumab may have an adverse effect on pregnancy and poses a risk to the human fetus, including embryo-lethality. Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 5 months (150 days) after the last dose of study agent. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.

  • Ability to understand and the willingness to sign a written informed consent document or a parent/guardian able to do the same.

Exclusion criteria:

  • Any prior therapy must have been completed greater than or equal to 4 weeks or 5 half-lives if known prior to enrollment on protocol and the participant must have recovered to eligibility levels from prior toxicity. Patients should be at least 6 weeks out from nitrosoureas and mitomycin C. Prior definitive radiation should have been completed greater than or equal to 4 weeks or palliative radiation should have been completed greater than or equal to 2 weeks prior to study enrollment and all associated toxicities resolved to eligibility levels. Patients who have had prior monoclonal antibody therapy must have completed that therapy at least 3 half-lives of the antibody or 6 weeks ago. Patients who have received more than a cumulative dose of 350 mg/m(2) of doxorubicin may be enrolled at the discretion of the Coordinating Center PI, with a screening echocardiogram.

  • Prior treatment with anti-PD-1, or anti-PD-L1 therapeutic antibody or pathway-targeting agents.

  • Patients who have received prior treatment with anti-CTLA-4 may be enrolled, provided the following requirements are met: Minimum of 12 weeks from the first dose of anti-CTLA-4 and >6 weeks from the last dose; No history of severe immune-related adverse effects from anti-CTLA-4 (NCI NCI CTCAE Grade 3 and 4)

  • Treatment with any other investigational agent within 4 weeks prior to Cycle 1, Day 1. Patients must be greater than or equal to 2 weeks since any investigational agent administered as part of a Phase 0 study (also referred to as an early Phase I study or pre-Phase I study where a subtherapeutic dose of drug is administered) at the Coordinating Center PI s discretion, and should have recovered to eligibility levels from any toxicities.

  • Treatment with systemic immunostimulatory agents (including, but not limited to, interferon-alpha or interleukin-2) within 6 weeks prior to Cycle 1, Day 1.

  • Treatment with systemic immunosuppressive medications (including, but not limited to, prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 2 weeks prior to Cycle 1, Day 1.

  • Patients who have received acute, low dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea) may be enrolled.

  • The use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowed.

  • Patients taking bisphosphonate therapy for symptomatic hypercalcemia. Use of bisphosphonate therapy for other reasons (e.g., bone metastasis or osteoporosis) is allowed.

  • Patients with known primary central nervous system (CNS) malignancy or symptomatic CNS metastases are excluded, with the following exceptions:

  • Patients with asymptomatic untreated CNS disease may be enrolled, provided all of the following criteria are met:

  • Evaluable or measurable disease outside the CNS

  • No metastases to brain stem, midbrain, pons, medulla, cerebellum, or within 10 mm of the optic apparatus (optic nerves and chiasm)

  • No history of intracranial hemorrhage or spinal cord hemorrhage

  • No ongoing requirement for dexamethasone for CNS disease; patients on a stable dose of anticonvulsants are permitted.

  • No neurosurgical resection or brain biopsy within 28 days prior to Cycle 1, Day 1

  • Patients with asymptomatic treated CNS metastases may be enrolled, provided all the criteria listed above are met as well as the following:

  • Radiographic demonstration of improvement upon the completion of CNS-directed therapy and no evidence of interim progression between the completion of CNS-directed therapy and the screening radiographic study

  • No stereotactic radiation or whole-brain radiation within 28 days prior to Cycle 1, Day 1

  • Screening CNS radiographic study greater than or equal to 4 weeks from completion of radiotherapy and greater than or equal to 2 weeks from discontinuation of corticosteroids

  • Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies.

  • History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins

  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.

  • Pregnant women are excluded from this study because atezolizumab is an investigational agent with the unknown potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with atezolizumab, breastfeeding should be discontinued if the mother is treated with atezolizumab.

  • HIV-positive patients may be on combination antiretroviral therapy but must have a CD4 count >350 cells/mm(3) with an undetectable viral load.

  • Patients on supraphysiologic doses of steroids or use of such within the previous six weeks.

  • Known clinically significant liver disease, including active viral, alcoholic, or other hepatitis; cirrhosis; fatty liver; and inherited liver disease.

  • Patients with past or resolved hepatitis B infection (defined as having a negative hepatitis B surface antigen [HBsAg] test and a positive anti-HBc [antibody to hepatitis B core antigen] antibody test) are eligible.

  • Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV RNA.

  • History or risk of autoimmune disease, including, but not limited to, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener s granulomatosis, Sj(SqrRoot)(Delta)gren s syndrome, Bell s palsy, Guillain-Barr(SqrRoot)(Copyright) syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis, or glomerulonephritis.

  • Patients with a history of autoimmune hypothyroidism on a stable dose of thyroid replacement hormone may be eligible.

  • Patients with controlled Type 1 diabetes mellitus on a stable insulin regimen may be eligible.

  • Patients with eczema, psoriasis, lichen simplex chronicus of vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis would be excluded) are permitted provided that they meet the following conditions:

  • Patients with psoriasis must have a baseline ophthalmologic exam to rule out ocular manifestations

  • Rash must cover less than 10% of body surface area (BSA)

  • Disease is well controlled at baseline and only requiring low potency topical steroids (e.g., hydrocortisone 2.5%, hydrocortisone butyrate 0.1%, flucinolone 0.01%, desonide 0.05%, aclometasone dipropionate 0.05%)

  • No acute exacerbations of underlying condition within the last 12 months (not requiring psoralen plus ultraviolet A radiation [PUVA], methotrexate, retinoids, biologic agents, oral calcineurin inhibitors; high potency or oral steroids)

  • History of idiopathic pulmonary fibrosis, pneumonitis (including drug induced), organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia, etc.), or evidence of active pneumonitis on screening chest computed tomography (CT) scan. History of radiation pneumonitis in the radiation field (fibrosis) is permitted.

  • Patients with active tuberculosis (TB) are excluded.

  • Severe infections within 4 weeks prior to Cycle 1, Day 1, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia.

  • Signs or symptoms of infection within 2 weeks prior to Cycle 1, Day 1.

  • Received oral or intravenous (IV) antibiotics within 2 weeks prior to Cycle 1, Day 1. Patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are eligible.

  • Major surgical procedure within 28 days prior to Cycle 1, Day 1 or anticipation of need for a major surgical procedure during the course of the study.

  • Administration of a live, attenuated vaccine within 4 weeks before Cycle 1, Day 1 or anticipation that such a live, attenuated vaccine will be required during the study and up to 5 months after the last dose of atezolizumab. --Influenza vaccination should be given during influenza season only (approximately October to March). Patients must not receive live, attenuated influenza vaccine within 4 weeks prior to Cycle 1, Day 1 or at any time during the study.

  • Patients requiring treatment with a RANKL inhibitor (e.g. denosumab) who cannot discontinue it before treatment with atezolizumab.

Recruitment period
From April 12, 2017
UC Davis Comprehensive Cancer Center
2279 45th Street
Sacramento, CA 95817
Research Topic
  • Soft Tissue Sarcoma

Have any questions or want to learn more? Leave your contact details below and the research team will reach out to you.


Send SMS with Study Info:

SMS Sent!

Share Study Info via Email:

E-mail Preview